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Abstract 
Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its 
efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been 
used pre‑operatively to downstage tumours with large soft tissue extension to allow for less morbid surgery. The 
role of Denosumab for conventional limb GCT of bone is yet to be defined. Further studies are required to determine 
whether local recurrence rates will be decreased with the adjuvant use of Denosumab along with surgery. The long 
term use and toxicity of this agent is unknown as is the proportion of patients with primary or secondary resistance. 
It is advised that complicated cases of GCT requiring Denosumab treatment should be referred and followed up at 
expert centres. Collaborative studies involving further clinical trials and rigorous data collection are strongly recom‑
mended to identify the optimum use of this drug.
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Background
Giant cell tumour of bone (GCT) is a bone neoplasm 
which is locally aggressive and can rarely metastasize. 
Histone 3.3 mutations of the H3F3A gene were recently 
described for GCT of bone and may prove useful in clari-
fying diagnosis in challenging cases [1]. The incidence of 
GCT of bone has not been completely established but it 
is around half as common as osteosarcoma. This would 
suggest an incidence of around 1.5/million population 
per year. GCT typically arises at the end of a long bone 
in a skeletally mature individual but can also arise in the 
axial skeleton and occasionally in children. The standard 
treatment is surgery aiming for as near complete removal 
of the tumour as is possible without major morbidity. 
This is usually by detailed curettage, although in tumours 
with extensive bone destruction, resection or even 
amputation may be required. Adjuvant therapies dur-
ing or after surgery such as the concomitant use of bone 
cement, phenol, ethanol, cryotherapy, or intravenous and 
oral bisphosphonates have been advocated to try and 
decrease the risk of local recurrence, but no randomised 
trial has ever been carried out to prove the efficacy of 
any of these [2–6]. Local recurrence is reported to occur 
in between 19–50  % of cases and usually arises within 
2 years [4, 7–9]. Local recurrence can often be treated by 
repeat curettage but sometimes requires more morbid 
surgery to achieve complete tumour clearance.
GCTs with extensive soft tissue extension (grade 3 
according to Campanacci grade 3 by radiology) and 
those of the axial skeleton are particularly challenging 
to treat and have been shown to have higher local recur-
rence rates [10–12]. In some cases, GCT of the spine and 
skull can be deemed inoperable, with complete tumour 
removal by surgery impossible due to the proximity of 
vital structures [12, 13]. Treatment in these difficult 
cases usually consists of debulking surgery (incomplete 
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removal) and/or the use of adjuvants such as emboliza-
tion [14, 15], radiation therapy [11, 16, 17], bisphospho-
nates [18, 19], and more recently, Denosumab [20, 21]. 
Conventional cytotoxic chemotherapy is not active in 
classic GCT of bone, even if anecdotal responses to oste-
osarcoma-like regimens containing platinum and anthra-
cyclines have been reported in the metastastic setting 
[22–24].
Denosumab
Denosumab is a fully humanised monoclonal antibody 
to RANK ligand (RANKL). Denosumab inhibits RANK-
RANKL interaction, a key mediator of osteoclast activity, 
thereby resulting in reduction of osteoclast-induced bone 
destruction [25, 26]. Denosumab is currently approved 
by the FDA and European Medical Agency (EMA) for 
osteoporosis and also for prevention of skeletal related 
events in bone metastases from solid tumors.
Neoplastic stromal cells of GCT overexpress RANKL 
and activate osteoclast-like giant cells [27–29]. Deno-
sumab treatment in GCT has been shown to reduce the 
number of tumour giant cells and neoplastic stromal 
cells and allow new bone formation [30]. The activity 
of Denosumab, dosed at 120  mg administered subcuta-
neously every 28 days with loading doses on days 8 and 
15 (of the first month of therapy) was confirmed in a 
proof-of-principle phase II study on 37 GCT patients 
[25]. Tumor response was confirmed in 30 of 35 evalu-
able patients (86  %). Denosumab showed an improve-
ment in Quality of Life (primary end point of the study) 
and good response in patients with inoperable GCT and 
reduced the need for otherwise morbid surgery in a sec-
ond, larger phase 2 clinical trial [26]. Enrolled patients 
were separated into three cohorts: surgically unsalvage-
able GCT consisted mainly of patients with sacral and 
spinal GCT as well as metastatic pulmonary disease 
(cohort 1), patients who were planned for morbid sur-
gery i.e. joint replacement, amputation, hemipelvectomy 
or major neurologic sequelae (e.g. base of skull tumours) 
(cohort 2) and those who transferred from the previous 
study of Denosumab (cohort 3). Cohort 1 showed no dis-
ease progression in 96 % (n = 163/169) of patients. 74 % 
of Cohort 2 (n = 74/100) in the trial did not need surgery 
while for those that did have surgery, 62  % (n =  16/26) 
required less morbid surgery than initially planned before 
Denosumab treatment. These data resulted in the FDA 
approval in June 2013 in adults and skeletally mature 
adolescents with giant cell tumour of bone deemed unre-
sectable or requiring morbid surgery or in metastatic 
disease [31]. The EMA has also recently approved Deno-
sumab for similar indications.
Administered as described above, Denosumab was 
generally well tolerated in trial patients but severe 
adverse events reported in the use of Denosumab include 
severe hypocalcaemia, osteonecrosis of the jaw (ONJ), 
and atypical stress fractures [26]. However, the cumula-
tive and long term incidence of these toxicities remains 
to be accurately delineated and reported.
Since its introduction for use in GCT over 5  years 
ago, the reported cases treated with Denosumab has 
grown exponentially with at least 19 case reports and six 
case series being published in Pubmed from January to 
November 2015 alone. Whilst the FDA and EMA have 
specific criteria for Denosumab use in GCT of bone, clin-
ical guidelines for use outside these criteria are lacking. 
Questions remain as to its recommended indications as 
well as the optimal duration of therapy. This is even more 
important as GCTB more often affects a young popu-
lation of patients with a very long life expectancy. The 
potential of collaborative research projects to address 
these issues were discussed by the authors in a recent 
international meeting (November 2015) [32]. The results 
of those discussions are presented here.
Current use of Denosumab in GCT of bone: indications 
and controversies
Locally advanced surgically unresectable and metastatic 
disease
The standard indication for Denosumab treatment is 
when there is no option of complete surgical removal of 
the tumour [26], such as tumours arising in the skull or 
spine or in the metastatic setting. Mattei reported a case 
of a 22 year old female with GCT of the C2 vertebral body 
and odontoid process successfully treated with Deno-
sumab with a 16-month follow-up [21]. Recurrent GCT 
of the cervical spine after curettage and reconstruction 
presents a scenario without a surgical solution (Fig.  1). 
Treatment with Denosumab was associated with prompt 
pain relief and resolution of neurology. Denosumab has 
also been used successfully for control of metastatic lung 
disease [33–36].
Controversy exists however on how long treatment 
should be continued and what the long-term effects 
of such treatment may be. There is major concern that 
Denosumab withdrawal is associated with a high rate of 
subsequent tumour recurrence [37, 38] suggesting that 
Denosumab alone is insufficient to achieve pathological 
complete response. There is currently insufficient data to 
quantify this risk but many recurrences will arise within 
7–9  months of stopping treatment. It is also not clear 
whether a rechallenge of Denosumab in case of second-
ary progression can achieve a new response. Mak et  al. 
[37] studied GCT cell cultures and found that although 
Denosumab treated specimens did not show any giant 
cells, neoplastic stromal cells persisted and continued 
to proliferate albeit at a slower rate than untreated GCT. 
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This may be explained by Lau et  al.’s [38] findings that 
Denosumab caused only minimal inhibitory effects on 
GCT stromal cell lines and did not cause any apoptosis. 
Girolami et al. [39] found H3F3A mutation in pre-treat-
ment and post-treatment surgical specimen of GCT of 
bone, supporting the hypothesis that the drug does not 
eliminate tumour cells.
It is therefore critical to rigorously evaluate in a pro-
spective clinical trial the risk of relapse when patients 
stop Denosumab. Furthermore analysis of the ongoing 
prospective phase II trial data is essential in this regard. 
If tumour recurrence is inevitable once Denosumab 
treatment is stopped, then patients with inoperable dis-
ease may either need to receive long term treatment to 
prevent tumour progression or reconsideration may be 
made to alternative, definitive therapies such as radio-
therapy [16, 17]. In females who wish to conceive and 
become pregnant, this will be a major concern as there 
is evidence that Denosumab is associated with increased 
still birth and decreased growth in animal infant studies 
[40]. Females on Denosumab are thus advised to avoid 
pregnancy and take appropriate contraceptive precau-
tions while on the drug.
The long term effects of prolonged treatment with 
Denosumab are unknown and skeletal events due to sup-
pressed bone turnover, such as atypical stress fractures 
[41] and critical hypercalcemia [35, 42] are of concern. 
The risk of ONJ has been reported to increase with the 
number and length of duration of Denosumab infusions 
[43] and this is a major concern in a benign tumour 
affecting young patients with little expected mortal-
ity secondary to disease. Chawla et al. [44] also recently 
presented data showing the increasing risk of toxic-
ity after 2  years of treatment. Sustained continued use 
of Denosumab may need to be supplemented with rest 
periods (or ‘drug holidays’) as described for long term 
bisphosphonate use to minimise risk of atypical stress 
fractures in appropriate patients. If the clinical decision 
is made to stop Denosumab in the setting of inoperable 
disease, consideration may be given to using bone turno-
ver markers to guide when Denosumab is to be restarted 
to prevent progressive disease recurrence. Urinary 
N-telopeptide and serum C-telopeptide determination 
show rapid decrease in levels once Denosumab treat-
ment is started [25]. Tartrate-resistant acid phosphatase 
5b, a bone resorption marker secreted by osteoclasts has 
also been shown to correlate with osteoclast activity sys-
temically [45]. These biomarkers could be used to indi-
cate when Denosumab has washed out of the system and 
potentially herald tumour recurrence.
Another approach to minimising adverse events in 
patients requiring long term treatment may be decreas-
ing dose frequency once a steady state (9–12 months on 
Denosumab or maybe even less) has been achieved. In a 
phase 2 clinical trial, Denosumab given at a 12 week dos-
ing schedule did not sustain suppression of bone turno-
ver markers as well as a 4  week dosing schedule [46]. 
However, these results were in patients who had not yet 
achieved a steady state on the drug, which could explain 
the drop off in activity. Agrawal et al. [20] have used Den-
osumab given every 3  months as a ‘maintenance’ dose 
after treatment of extensive spinal disease. Importantly, 
it is not yet clear whether alterations in dosing schedule 
or drug holidays affect the longevity of tumour response.
Neoadjuvant use in difficult, locally advanced Campanacci 3 
tumours
GCT of the pelvis, sacrum, and spine are associated with 
high local recurrence rates and significant surgical mor-
bidity with conventional surgical treatment [11, 12, 14, 
15, 47]. There are some case reports on axial GCTs where 
neo-adjuvant treatment with Denosumab helped make 
Fig. 1 a Acute cervical cord compression secondary to collapse of giant cell tumour in C4 vertebrae. b 4 weeks from emergency decompression 
and stabilization, patient developed tumour recurrence (arrow) causing canal compression. c MRI scan after 3 months of Denosumab showing 
decrease in tumour mass (arrow) and decompression of spinal canal
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surgery possible [20, 48, 49]. In addition to the benefit of 
reducing tumor volume, the potential of Denosumab to 
reduce blood loss from intralesional curettage of pelvic 
GCT is alluded to by Watanabe et al. [45]. A retrospective 
analysis of a single institution experience from Girolami 
et  al. [39] documented a conversion of the neoplastic 
stromal cells to a fibrous matrix with decreased angio-
genesis, which could explain the decreased vascularity of 
the treated tumours. In a sub-study of the phase II clini-
cal trial assessing 222 patients for possible downstaging 
with denosumab for planned surgery [50], the majority 
of patients after surgery received adjuvant Denosumab 
for 6 months. Of the 116 patients who had surgery (with 
median postsurgical follow-up of only 13 months), local 
recurrence occurred in 17 (15 %) patients—the majority 
of these patients underwent local excision only.
Campanacci 3 lesions treated with curettage are asso-
ciated with higher local recurrence rates versus Cam-
panacci 1 or 2 lesions [4, 10]. In extensive grade 3 lesions, 
the extension of the tumour into the soft tissues as well 
as involvement of the articular cartilage usually means 
that an effective curettage is not always possible and 
these cases may be better treated with a resection of the 
involved bone. Denosumab treatment in GCT causes a 
rim of new bone to form [30, 51], which effectively con-
verts what was previously a Campanacci 3 lesion to a 
lesser grade. With an increasing rim of ossified bone on 
the periphery, intralesional curettage is more possible 
[52].
There is concern however about the ability to do an 
effective extended curettage after Denosumab treat-
ment. Although the newly formed bone on the periphery 
allows for a sufficient mechanical scaffold for curettage to 
be done without fear of the bone collapsing, the rim of 
new bone may contain neoplastic cells that may reacti-
vate once Denosumab treatment is finished. In the phase 
2 clinical trial, the median time to surgery after Deno-
sumab treatment was around 2 years and after this length 
of time on the drug, the rim of new bone and ossification 
on the periphery of the tumour is quite thick, such that 
the probability of leaving behind neoplastic tissue would 
be quite high. In this situation, an adjuvant such as liquid 
nitrogen that penetrates throughout the ‘new bone’ that 
has formed may be beneficial [53]. Performing definitive 
surgery much earlier (3–4  months after starting Deno-
sumab) to prevent too thick a rim of bone from forming 
may make complete removal much more feasible. There 
is also the possibility of keeping a patient on a mainte-
nance dose of Denosumab to prevent recurrence [20]. 
Whether this will be sufficient to maintain long term 
control remains unknown. A comparative study between 
neo-adjuvant Denosumab and curettage versus outright 
resection for extensive Campanacci 3 tumours is needed 
to accurately determine long term disease control and 
functional outcomes.
A different situation exists when wide radical surgery 
is planned after Denosumab therapy for tumours that 
are very advanced locally with a large soft tissue mass, 
joint involvement, or pathological fracture where pri-
mary amputation or wide resection is required for com-
plete tumour clearance. In these situations, reduction of 
tumour volume and calcification of the tumour penetrat-
ing into soft tissues after Denosumab therapy can facili-
tate or enable radical tumour resection. When en-bloc 
resection is planned neoadjuvant therapy should be used 
for longer time until maximal calcification of the tumor 
and response plateau is observed on consecutive imaging.
Progression and recurrence
The vast majority of patients on Denosumab will have 
clinical and radiological evidence of response, usually 
manifest by decrease in pain, increase in function and 
sometimes radiological shrinkage, often accompanied 
by a decrease in activity on PET scan and formation of 
calcification. Using conventional radiological criteria, 
response by RECIST which is based on decreases in 
tumour diameter do not adequately describe the thera-
peutic response to Denosumab due to minimal tumour 
shrinkage [54]. Using EORTC criteria, which incorporate 
changes in PET-FDG uptake, and inverse Choi, measur-
ing increase in density with calcification of the tumour, 
Denosumab has shown good response for GCT of bone 
compatible with the clinical improvement seen in the 
majority of patients on the drug [26, 54]. Denosumab 
activity often results in osteosclerosis, calcified rim for-
mation, and reconstitution of cortical bone often with-
out significant changes in overall dimensions that can 
be detected on conventional radiographs and computed 
tomography. On dynamic contrast-enhanced magnetic 
resonance imaging (MRI), later enhancement followed 
by slower washout compared with index MRI may indi-
cate response to treatment, usually the infiltration within 
soft tissues is decreased. The optimal radiologic tool for 
assessment is not yet known although MRI scans seem 
to be adequate to document response to treatment while 
CT scans may be used to monitor reconstitution of the 
cortical rim for surgical planning.
Data on GCT of bone patients resistant to Denosumab 
are scanty and the final analysis of the phase II study is 
awaited. The latter must include the incidence of compli-
cations from treatment as well as the rates of local recur-
rence in patients who have had surgical resection, be it a 
complete excision or curettage. Overall, available data 
show that progression while on treatment is unusual [26] 
and is usually associated with increase in pain and size 
of the lesion. In some situations part of a tumour may 
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progress while other areas remain controlled and the 
mechanism of this is not clear. In tumours that do not 
respond to Denosumab from the beginning or after an ini-
tial response, both the original biopsy and recurrent tissue 
should be carefully reviewed to exclude malignant GCT or 
other giant-cell rich pathology. There are isolated reports 
of ‘benign’ GCTs recurring as ‘malignant’ following Den-
osumab treatment but the incidence of this is unknown 
[55]. Finally, molecular mechanisms of resistance to Deno-
sumab in GCTB are still left to be fully understood.
In patients who have stopped Denosumab (for what-
ever reason) and develop recurrence, anectodal reports 
suggest that if clinically indicated, Denosumab can be 
effective at treating recurrence which the final results of 
the phase II trial should answer.
Conclusions
Denosumab is an effective and useful drug for managing 
GCT of bone. It should be considered as the gold stand-
ard for first line treatment for patients with inoperable 
or metastatic GCT. The optimal treatment schedule in 
long term maintenance therapy with less frequent dos-
age is not known and should be the subject of ongoing 
research. Reintroduction of Denosumab following recur-
rence of GCT after stopping therapy for different rea-
sons seems to be an effective option. Denosumab can be 
used to downstage those with disease requiring morbid 
surgery, but the timing of use of neoadjuvant therapy in 
locally advanced Campanacci grade 3 tumors is debat-
able. Further randomized studies are required to deter-
mine whether local recurrence rates will be decreased 
with the adjuvant use of Denosumab along with sur-
gery. Fortunately, the numbers required to answer these 
questions seem to be achievable within reasonable 
timeframes, based on the successes of the initial and 
subsequent trials of Denosumab in GCT of bone [25, 
26, 54]. Safety for long term use is unknown and should 
be reported as soon as possible with the full dataset of 
the large phase II study. Due to the challenges of treat-
ing this disease and the unanswered questions regard-
ing optimal use of Denosumab, referral and follow-up of 
complicated cases of GCT requiring Denosumab should 
be within expert centres with a multidisciplinary team. 
Further clinical trials are mandated to identify the opti-
mum indications for using Denosumab in GCT.
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